PMID- 22136882
OWN - NLM
STAT- MEDLINE
DCOM- 20120621
LR  - 20220311
IS  - 1872-7654 (Electronic)
IS  - 0301-2115 (Linking)
VI  - 160
IP  - 2
DP  - 2012 Feb
TI  - Metabolomic biomarkers of impaired glucose tolerance and type 2 diabetes mellitus 
      with a potential for risk stratification in women with polycystic ovary syndrome.
PG  - 121-30
LID - 10.1016/j.ejogrb.2011.11.005 [doi]
AB  - There is a need to identify biomarkers of impaired glucose tolerance (IGT) and 
      type 2 diabetes mellitus (T2DM) risk in women with PCOS to facilitate screening 
      and the development of novel strategies to prevent disease progression. 
      Metabolomic technologies may address this need. All published studies on 
      metabolomic biomarkers of IGT and/or T2DM identified through MEDLINE 
      (1966-December 2010), EMBASE (1980-December 2010) and Cochrane (1993-December 
      2010) were retrieved. Eligible studies were screened and specific study 
      characteristics recorded including study design, number of participants, 
      selection criteria, type of metabolomic technique used, site of sample 
      collection, and a list of metabolites identified to have been altered in IGT 
      and/or T2DM versus healthy controls was created. Nine metabolomic biomarkers that 
      could potentially be used to identify women with PCOS at risk of developing IGT 
      and/or T2DM were identified including leucine, isoleucine, citrate, glucose, 
      creatinine, valine, glutamine, alanine and HDL. Of these biomarkers, a panel of 
      four biomarkers were consistently either elevated or reduced including glucose 
      (elevated), valine (reduced), HDL (reduced) and alanine (reduced) in IGT/T2DM 
      compared with controls. These biomarkers may predict the development of IGT/T2DM 
      in young women with PCOS. More studies are required to test this hypothesis and 
      translate the findings into patient benefit by reducing the morbidity/mortality 
      associated with IGT/T2DM in PCOS.
CI  - Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
FAU - Galazis, Nicolas
AU  - Galazis N
AD  - Nottingham Medical School, University of Nottingham, Queens Medical Centre Campus 
      Nottingham University Hospitals, Nottingham NG7 2UH, United Kingdom. 
      mzybng@nottingham.ac.uk
FAU - Iacovou, Christos
AU  - Iacovou C
FAU - Haoula, Zeina
AU  - Haoula Z
FAU - Atiomo, William
AU  - Atiomo W
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20111201
PL  - Ireland
TA  - Eur J Obstet Gynecol Reprod Biol
JT  - European journal of obstetrics, gynecology, and reproductive biology
JID - 0375672
RN  - 0 (Biomarkers)
RN  - 0 (Lipoproteins, HDL)
RN  - HG18B9YRS7 (Valine)
RN  - OF5P57N2ZX (Alanine)
SB  - IM
MH  - Adult
MH  - Alanine/blood
MH  - Biomarkers/blood
MH  - Diabetes Mellitus, Type 2/*blood/*complications/epidemiology/physiopathology
MH  - Female
MH  - Glucose Intolerance/*blood/*complications/epidemiology/physiopathology
MH  - Humans
MH  - Hyperglycemia/etiology
MH  - Lipoproteins, HDL/blood
MH  - Metabolomics/methods
MH  - Polycystic Ovary Syndrome/*complications
MH  - Risk
MH  - Valine/blood
EDAT- 2011/12/06 06:00
MHDA- 2012/06/22 06:00
CRDT- 2011/12/06 06:00
PHST- 2011/07/09 00:00 [received]
PHST- 2011/09/23 00:00 [revised]
PHST- 2011/11/05 00:00 [accepted]
PHST- 2011/12/06 06:00 [entrez]
PHST- 2011/12/06 06:00 [pubmed]
PHST- 2012/06/22 06:00 [medline]
AID - S0301-2115(11)00625-7 [pii]
AID - 10.1016/j.ejogrb.2011.11.005 [doi]
PST - ppublish
SO  - Eur J Obstet Gynecol Reprod Biol. 2012 Feb;160(2):121-30. doi: 
      10.1016/j.ejogrb.2011.11.005. Epub 2011 Dec 1.